Clinical Trial Update: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating SL-279252, a PD-1-Fc-OX40L fusion protein, in adults with advanced solid tumors or lymphomas has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma
• Hodgkin Lymphoma
• Melanoma
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Cervix
• Squamous Cell Carcinoma of the Head and Neck
• Urothelial Carcinoma

Drugs mentioned

• SL-279252 (PD1-Fc-OX40L) (PD-1-Fc-OX40L fusion protein)

Snippet

Sponsor: Shattuck Labs, Inc. | Conditions: Squamous Cell Carcinoma of the Head and Neck, Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2025-03-14